Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Skeletal muscle atrophy and Spinal muscular atrophy.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 2 | Skeletal muscle atrophy, Spinal muscular atrophy |
Bones and joints |
3 FDA-approved treatments are available for spinal muscular atrophy, facioscapulohumeral type, including NUSINERSEN (SPINRAZA, approved 2016), onasemnogene abeparvovec-xioi (Zolgensma, approved 2019), and RISDIPLAM (EVRYSDI, approved 2020).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|
No clinical trials have been registered for spinal muscular atrophy, facioscapulohumeral type.
3 publications have been identified in PubMed for spinal muscular atrophy, facioscapulohumeral type. Research spans Other (33%), Review / Meta-Analysis (33%), and Epidemiology / Natural History (33%).
Deenen JC (2025). [PMID: 40034005](https://pubmed.ncbi.nlm.nih.gov/40034005/). *Journal of neuromuscular diseases*. [Epidemiology / Natural History]
Poulsen NS (2025). [PMID: 40033997](https://pubmed.ncbi.nlm.nih.gov/40033997/). *Journal of neuromuscular diseases*. [Review / Meta-Analysis]
Riuzzi F (2024). [PMID: 38651523](https://pubmed.ncbi.nlm.nih.gov/38651523/). *European journal of translational myology*. [Other]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 7:59 AM UTC
Online Mendelian Inheritance in Man
Skeletal muscle atrophy |
EVRYSDI | RISDIPLAM | — | 2020 | Available |
Zolgensma | onasemnogene abeparvovec-xioi | — | 2019 | Available |
SPINRAZA | NUSINERSEN | — | 2016 | Available |
View trials for spinal muscular atrophy, facioscapulohumeral type